Purple Biotech (PPBT) Total Current Liabilities (2017 - 2021)

Purple Biotech (PPBT) has disclosed Total Current Liabilities for 5 consecutive years, with $4.2 million as the latest value for Q4 2021.

  • On a quarterly basis, Total Current Liabilities rose 37.19% to $4.2 million in Q4 2021 year-over-year; TTM through Dec 2021 was $4.2 million, a 37.19% increase, with the full-year FY2021 number at $4.2 million, up 37.19% from a year prior.
  • Total Current Liabilities was $4.2 million for Q4 2021 at Purple Biotech, up from $3.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $4.2 million in Q4 2021 to a low of $3.1 million in Q4 2020.
  • A 5-year average of $3.6 million and a median of $3.5 million in 2019 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: fell 16.59% in 2018, then surged 37.19% in 2021.
  • Purple Biotech's Total Current Liabilities stood at $4.0 million in 2017, then decreased by 16.59% to $3.3 million in 2018, then increased by 7.0% to $3.5 million in 2019, then decreased by 12.63% to $3.1 million in 2020, then surged by 37.19% to $4.2 million in 2021.
  • Per Business Quant, the three most recent readings for PPBT's Total Current Liabilities are $4.2 million (Q4 2021), $3.1 million (Q4 2020), and $3.5 million (Q4 2019).